![]() ![]() Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Ĭautionary Note Regarding Forward-Looking Statements The Company is headquartered in Wexford, PA. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. Coeptis' product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. ![]() Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at Coeptis Therapeutics Holdings, Inc.Ĭoeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. When available, copies of the final prospectus can be obtained at the SEC's website at or from Ladenburg Thalmann & Co. A final prospectus relating to this offering will be filed by Coeptis with the SEC. A preliminary prospectus relating to the proposed offering was filed with the SEC on Jand is available on the SEC's website located at. The offering is being made solely by means of a prospectus. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. 333-269782), which was declared effective by the United States Securities and Exchange Commission ("SEC") on June 13, 2023, and related MEF registration statements on Form S-1 that was filed with the SEC on Jand June 14, 2023. The securities are being offered pursuant to a registration statement on Form S-1 (File No. is acting as sole book-running manager in connection with this offering. The closing of the offering is expected to take place on or about June 16, 2023, subject to the satisfaction or waiver of customary closing conditions. The pre-funded warrant is exercisable at $0.0001. The warrants issued in this offering are fixed priced and do not contain any variable pricing, resets or priced based anti-dilution features. The offering is comprised of (i) 2,150,000 shares of common stock, (ii) 1,350,000 pre-funded warrants, (iii) 3,062,500 Series A Warrants with an exercise price of $1.65 per share and a term of five years following the initial exercise date, and (iv) 3,062,500 Series B Warrants with an exercise price of $1.65 per share and a term of five years following the initial exercise date. ![]()
0 Comments
Leave a Reply. |